Ignite Creation Date:
2025-12-24 @ 7:21 PM
Ignite Modification Date:
2025-12-28 @ 11:21 PM
Study NCT ID:
NCT05232903
Status:
UNKNOWN
Last Update Posted:
2022-03-02
First Post:
2021-12-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Stromal Vascular Fraction (SVF) Therapy in Patients With Acute Spontaneous Intracerebral Hemorrhage (SICH).
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SEQUENTIAL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 15}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2022-03-01', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2022-02', 'completionDateStruct': {'date': '2024-09-30', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2022-02-12', 'studyFirstSubmitDate': '2021-12-06', 'studyFirstSubmitQcDate': '2022-02-09', 'lastUpdatePostDateStruct': {'date': '2022-03-02', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2022-02-10', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-06-30', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Occurrence of adverse events', 'timeFrame': '1 year', 'description': 'Number of adverse events at each Stromal vascular fraction (SVF) dose following infusion.'}], 'secondaryOutcomes': [{'measure': 'The changes in stroke-related neurologic deficit', 'timeFrame': 'baseline, Month 1, Month 3, Month 6, Month 9, Month 12', 'description': 'The changes in stroke-related neurologic deficit were measured by the National Institute of Health stroke scale (NIHSS), which ranges from 0 to 45. Higher scores indicate worse neurological function.'}, {'measure': "The changes in patients' language function", 'timeFrame': 'baseline, Month 1, Month 3, Month 6, Month 9, Month 12', 'description': "The changes in patients' language function were measured by the Western Aphasia Battery (WAB), which ranges from 0 to 100. Higher scores indicate better language function."}, {'measure': "The changes in patients' sensorimotor function", 'timeFrame': 'baseline, Month 1, Month 3, Month 6, Month 9, Month 12', 'description': "The changes in patients' language function were measured by the Fugl-Meyer Assessment (FMA), which ranges from 0 to 226. Higher scores indicate better language function."}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Spontaneous intracerebral hemorrhage', 'Stromal vascular fraction'], 'conditions': ['Spontaneous Intracerebral Hemorrhage']}, 'descriptionModule': {'briefSummary': 'The purpose of this pilot study is to evaluate the safety of stromal vascular fraction (SVF) therapy in patients with spontaneous intracerebral hemorrhage (SICH).', 'detailedDescription': "Spontaneous intracerebral hemorrhage (SICH) is a form of brain parenchymal hemorrhage caused by various non-traumatic reasons, resulting in cerebral artery, veins or capillaries rupture. SICH is a common neurological emergency with the characteristics of rapid onset, dangerous conditions, and a high disability and fatality rate. Although the fatality rate has decreased, reflecting the progress of recent medical technologies, most patients still have persistent language or limb movement dysfunction.\n\nStromal vascular fraction (SVF) is a structural framework in the body's fat tissue, comprising mesenchymal stem cells, white blood cells, red blood cells, endothelial cells, T cells, platelets related cytokines. Previous studies have demonstrated that SVF has favorable therapeutic effects against various diseases regarding different systems, including the motor system, respiratory system, circulatory system, and nervous system, which indicated the treatment potential of SVF in the treatment of SICH.\n\nThe overall clinical development strategy of this project is to conduct a Phase I dose-escalation study to evaluate the safety of SVF therapy in patients with SICH. Fifteen patients with SICH will be sequentially assigned to 3 dose groups, and the adverse events (AEs) and serious adverse events (SAEs) will be recorded in a period of 1 year."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '55 Years', 'minimumAge': '45 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Age range: 45\\~55 years old\n2. Acute spontaneous supratentorial ICH documented by head CT with GCS Score between 8-12 inclusive.\n3. Stable ICH hematoma volume 60mL or less as measured by ABC2 method based on preoperative CT.\n4. Neurosurgical ICH evacuation can be performed within the first 72 h of ICH onset.\n5. Ability to provide written personal or surrogate consent.\n6. Expectancy life is longer than 12 months.\n7. Subject must be available for all specified assessments at the study site through the completion of the study.\n8. Determining Organ function according to the following criteria:\n\n1\\) Aspartate transaminase (AST) ≤2.5×Upper limit of normal 2) Alanine transaminase (ALT) ≤2.5×Upper limit of normal 3) Total bilirubin (T-Bil) ≤1.5×Upper limit of normal 4) Serum albumin (SA) ≥3.0g/dL 5) Absolute neutrophil count（ANC）≥1.5×10\\^9/L 6) Platelets (PLT) ≥150×10\\^9/L 7) Hemoglobin (Hb) ≥9.0g/dL 8) Creatine kinase (CK) ≤1.5×Upper limit of normal 9) Serum amylase (AMY) and serum lipase (Lip) are within the normal range\n\nExclusion Criteria:\n\n1. Secondary ICH related to aneurysm, AVM, trauma, brain tumor, etc.\n2. History of epilepsy.\n3. History of brain tumor.\n4. History of brain trauma.\n5. Pre-existing disability defined as a pre-stroke modified Rankin scale \\>2.\n6. Evidence of organ failure.\n7. Septicemia with high fever and shock.\n8. Positive for any one of hepatitis B surface antigens, e antigens, e antibodies, and core antibodies, hepatitis C virus antibodies, syphilis antibodies, or HIV antibodies positive.\n9. Participation in any clinical investigation within 3 months prior to dosing.\n10. Suffer from any other clinically significant medical diseases or with evidence of metal disorder.\n11. The investigator or sponsor determines that participating in the trial will bring safety risks to the patients.\n12. Participated in other stem cell therapy research.\n13. History of drug or alcohol abuse in the past year\n14. Women who are pregnant, breastfeeding, or planning to become pregnant during the trial\n15. Allergic to cattle and pork products.'}, 'identificationModule': {'nctId': 'NCT05232903', 'briefTitle': 'Stromal Vascular Fraction (SVF) Therapy in Patients With Acute Spontaneous Intracerebral Hemorrhage (SICH).', 'organization': {'class': 'OTHER', 'fullName': 'Beijing Tiantan Hospital'}, 'officialTitle': 'Safety of Stromal Vascular Fraction (SVF) Therapy in Patients With Acute Spontaneous Intracerebral Hemorrhage (SICH): a Phase I Clinical Study', 'orgStudyIdInfo': {'id': 'SICH-SVF'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Group 1 SVF dose 0.5 x 10^6/kg Intravenous infusion (IV)', 'description': 'Intravenous infusion of stromal vascular fraction (SVF) dose 0.5 x 10\\^6/kg for 5 participants within 1 month after neurosurgical intracerebral hemorrhage (ICH) evacuation.', 'interventionNames': ['Biological: SVF therapy group']}, {'type': 'EXPERIMENTAL', 'label': 'Group 2 SVF dose 1.0 x 10^6/kg Intravenous infusion (IV)', 'description': 'Intravenous infusion of stromal vascular fraction (SVF) dose 1.0 x 10\\^6/kg for next 5 participants within 1 month after neurosurgical intracerebral hemorrhage (ICH) evacuation.', 'interventionNames': ['Biological: SVF therapy group']}, {'type': 'EXPERIMENTAL', 'label': 'Group 3 SVF dose 1.5 x 10^6/kg Intravenous infusion (IV)', 'description': 'Intravenous infusion of SVF stromal vascular fraction (SVF) dose 1.5 x 10\\^6/kg for final 5 participants within 1 month after neurosurgical intracerebral hemorrhage (ICH) evacuation.', 'interventionNames': ['Biological: SVF therapy group']}], 'interventions': [{'name': 'SVF therapy group', 'type': 'BIOLOGICAL', 'description': "The active treatment is an intravenous injection with the stromal vascular fraction (SVF) harvested from the patient's own fatty tissue.", 'armGroupLabels': ['Group 1 SVF dose 0.5 x 10^6/kg Intravenous infusion (IV)', 'Group 2 SVF dose 1.0 x 10^6/kg Intravenous infusion (IV)', 'Group 3 SVF dose 1.5 x 10^6/kg Intravenous infusion (IV)']}]}, 'contactsLocationsModule': {'locations': [{'zip': '100070', 'city': 'Beijing', 'state': 'Beijing Municipality', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Yong Cao, M.D.', 'role': 'CONTACT', 'email': 'caoyong@bjtth.org', 'phone': '861067096510', 'phoneExt': '100070'}], 'facility': 'Beijing Tiantan Hospital Affiliated to Capital Medical University', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}], 'centralContacts': [{'name': 'Yong Cao, M.D.', 'role': 'CONTACT', 'email': 'caoyong@bjtth.org', 'phone': '861067096510', 'phoneExt': '100070'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Beijing Tiantan Hospital', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Clinical Professor', 'investigatorFullName': 'Dr. Yong Cao', 'investigatorAffiliation': 'Beijing Tiantan Hospital'}}}}